IMX 503Alternative Names: IMX503; Nosocomial pneumonia peptide - Inimex
Latest Information Update: 16 Jul 2016
At a glance
- Originator Inimex Pharmaceuticals
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Nosocomial pneumonia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-pneumonia in Canada
- 31 Mar 2004 Preclinical trials in Nosocomial pneumonia in Canada (unspecified route)